[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study.
Purpose: The use of [177Lu]Lu-PSMA-617 radioligand therapy has become increasingly recognized as a viable therapeutic approach for patients in the advanced stages of metastatic castration-resistant prostate cancer (mCRPC). However, there is limited data regarding its effectiveness and safety in earl...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 51; no. 8; pp. 2495 - 2504 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jul2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |